Profile data is unavailable for this security.
About the company
Innate Pharma SA is a France-based biopharmaceutical company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. It works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. It also has a multi-product partnership with AstraZeneca.
- Revenue in EUR (TTM)12.62m
- Net income in EUR-49.47m
- Incorporated1999
- Employees168.00
- LocationInnate Pharma SA117 avenue de Luminy, Bp 30191MARSEILLE 13009FranceFRA
- Phone+33 430303030
- Fax+33 430303000
- Websitehttps://www.innate-pharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Maat Pharma SA | 3.22m | -28.90m | 76.55m | 60.00 | -- | 6.42 | -- | 23.80 | -2.21 | -2.21 | 0.2462 | 0.7395 | 0.079 | 9.84 | 3.83 | 53,600.00 | -70.99 | -41.51 | -104.45 | -51.87 | 61.13 | -- | -898.79 | -976.99 | 1.89 | -32.75 | 0.6069 | -- | 44.34 | -- | -46.59 | -- | 42.53 | -- |
| Cellectis SA | 46.72m | -51.65m | 90.40m | 224.00 | -- | 0.9141 | -- | 1.93 | -0.5541 | -0.5541 | 0.49 | 1.37 | 0.1524 | -- | 4.58 | 208,560.50 | -16.59 | -21.50 | -29.99 | -29.24 | -- | -32.79 | -108.88 | -220.86 | -- | -7.06 | 0.442 | -- | 435.37 | 16.44 | 66.41 | -- | -21.58 | -- |
| Sensorion SA | 0.00 | -25.97m | 95.61m | 63.00 | -- | 1.32 | -- | -- | -0.0923 | -0.0923 | 0.00 | 0.2401 | 0.00 | -- | -- | 0.00 | -38.26 | -34.53 | -46.44 | -43.50 | -- | -- | -- | -- | -- | -- | 0.0285 | -- | -- | -- | -17.72 | -- | 98.90 | -- |
| Eurofins-Cerep SA | 40.46m | 7.15m | 103.91m | 207.00 | 14.52 | 1.45 | 10.86 | 2.57 | 1,418.43 | 1,418.43 | 8,027.24 | 14,234.14 | 0.4955 | 1.61 | 4.75 | 195,445.80 | 8.76 | 13.12 | 10.23 | 15.90 | 85.67 | 80.02 | 17.68 | 20.22 | 6.53 | -- | 0.0046 | -- | -8.20 | 5.46 | -6.34 | 10.36 | -- | -- |
| Transgene SA | 6.08m | -33.97m | 116.28m | 165.00 | -- | 7.60 | -- | 19.12 | -0.1633 | -0.1633 | 0.0523 | 0.1152 | 0.1392 | -- | 6.19 | 36,854.55 | -77.74 | -33.32 | -107.22 | -40.55 | -- | -- | -558.64 | -251.37 | -- | -- | 0.0118 | -- | -20.34 | -14.48 | -52.15 | -- | 12.68 | -- |
| Ose Immunotherapeutics SA | 83.44m | 37.45m | 116.50m | 64.00 | 3.72 | 1.74 | 2.86 | 1.40 | 1.37 | 1.37 | 3.55 | 2.91 | 0.81 | -- | 32.59 | 1,303,672.00 | 36.35 | -7.66 | 44.85 | -9.27 | -- | -- | 44.88 | -26.10 | -- | 14.19 | 0.4196 | -- | 3,646.52 | 26.31 | 262.78 | -- | -25.52 | -- |
| Innate Pharma SA | 12.62m | -49.47m | 143.80m | 168.00 | -- | 14.80 | -- | 11.39 | -0.61 | -0.61 | 0.1556 | 0.1054 | 0.0882 | -- | 0.4171 | -- | -34.57 | -13.29 | -46.32 | -17.34 | 52.73 | -- | -391.94 | -88.46 | -- | -- | 0.9001 | -- | -75.68 | -28.80 | -553.51 | -- | -64.08 | -- |
| Genfit SA | 70.94m | 1.51m | 165.21m | 180.00 | 91.17 | 2.39 | 50.91 | 2.33 | -0.0716 | -0.0716 | 1.28 | 1.38 | 0.4362 | 512.25 | 5.44 | 394,105.60 | 0.9265 | -7.73 | 1.42 | -9.79 | 97.11 | 95.68 | 2.12 | -37.15 | 1.23 | 1.45 | 0.473 | -- | 85.82 | 11.61 | 105.22 | -- | -13.57 | -- |
| Nanobiotix SA | -11.61m | -68.13m | 187.83m | 108.00 | -- | -- | -- | -- | -1.44 | -1.44 | -0.2456 | -1.39 | -0.1439 | -- | -- | -107,490.70 | -84.47 | -54.39 | -259.52 | -90.60 | -- | -- | -- | -1,326.20 | -- | -27.67 | -- | -- | -138.62 | -- | -71.62 | -- | -10.10 | -- |
| Holder | Shares | % Held |
|---|---|---|
| CDC Croissance SAas of 25 Apr 2025 | 930.02k | 1.11% |
| CPR Asset Management SAas of 30 Apr 2025 | 491.60k | 0.59% |
| Saint Olive Gestion SNCas of 29 Dec 2023 | 250.00k | 0.30% |
| Cr�dit Mutuel Asset Management SAas of 27 Feb 2025 | 209.00k | 0.25% |
| Erasmus Gestion SASas of 03 Sep 2024 | 110.00k | 0.13% |
| Montpensier Arbevelas of 30 Dec 2022 | 58.50k | 0.07% |
| Claresco Finance SAas of 31 Dec 2024 | 25.00k | 0.03% |
| Dimensional Fund Advisors LPas of 05 Jun 2025 | 23.28k | 0.03% |
| Friedland Gestion SASas of 28 Feb 2025 | 7.10k | 0.01% |
